{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:43:55Z","timestamp":1793241835994,"version":"4.5.0"},"reference-count":198,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T00:00:00Z","timestamp":1610236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003495","name":"Hessisches Ministerium f\u00fcr Wissenschaft und Kunst","doi-asserted-by":"publisher","award":["III L 4-518\/17.004"],"award-info":[{"award-number":["III L 4-518\/17.004"]}],"id":[{"id":"10.13039\/501100003495","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Chronic myeloid leukemia (CML) has been a \u201cmodel disease\u201d with a long history. Beginning with the first discovery of leukemia and the description of the Philadelphia Chromosome and ending with the current goal of achieving treatment-free remission after targeted therapies, we describe here the journey of CML, focusing on molecular pathways relating to signaling, metabolism and the bone marrow microenvironment. We highlight current strategies for combination therapies aimed at eradicating the CML stem cell; hopefully the final destination of this long voyage.<\/jats:p>","DOI":"10.3390\/cells10010117","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T19:55:56Z","timestamp":1610308556000},"page":"117","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":152,"title":["Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9296-9403","authenticated-orcid":false,"given":"Valentina R.","family":"Minciacchi","sequence":"first","affiliation":[{"name":"Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Str. 42-44, 60596 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0934-0859","authenticated-orcid":false,"given":"Rahul","family":"Kumar","sequence":"additional","affiliation":[{"name":"Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Str. 42-44, 60596 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3603-1119","authenticated-orcid":false,"given":"Daniela S.","family":"Krause","sequence":"additional","affiliation":[{"name":"Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Str. 42-44, 60596 Frankfurt am Main, Germany"},{"name":"German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany"},{"name":"German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany"},{"name":"Frankfurt Cancer Institute, 60596 Frankfurt, Germany"},{"name":"Faculty of Medicine, Medical Clinic II, Johann Wolfgang Goethe University, 60596 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"(1975). Rudolf Virchow (1821\u20131902). CA Cancer J. Clin., 25, 91\u201392.","DOI":"10.3322\/canjclin.25.2.91"},{"key":"ref_2","unstructured":"Bennett, J.H. (1845). Case of Hypertrophy of the Spleen and Liver, which Death Took Place from Suppuration of the Blood. Edinb. Med. Surg. J., 413\u2013423."},{"key":"ref_3","unstructured":"Neumann, E. (1871). Ein Fall von Leuk\u00e4mie mit Erkrankung des Knochenmarks Anhang: Salkowski: Chemische Untersuchungen des leuk\u00e4mischen Markes. Archiv der Heilkunde, 1\u201315."},{"key":"ref_4","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Peter","year":"1960","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/306239a0","article-title":"Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia","volume":"306","author":"Heisterkamp","year":"1983","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood.V63.1.223.223","article-title":"Localization of the human c-sis oncogene in Ph1-positive and Ph1-negative chronic myelocytic leukemia by in situ hybridization","volume":"63","author":"Bartram","year":"1984","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/306277a0","article-title":"Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia","volume":"306","author":"Bartram","year":"1983","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","article-title":"Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"ref_11","first-page":"550","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nat. Cell Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198512053132301","article-title":"Evidence of a new chimeric bcr\/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome","volume":"313","author":"Stam","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/0092-8674(84)90438-0","article-title":"An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity","volume":"37","author":"Konopka","year":"1984","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","article-title":"The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene","volume":"233","author":"Daley","year":"1986","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1073\/pnas.85.23.9312","article-title":"Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr\/abl protein","volume":"85","author":"Daley","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis, C.M.L","volume":"351","author":"Jamieson","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","article-title":"The leukaemia stem cell: Similarities, differences and clinical prospects in CML and AML","volume":"20","author":"Vetrie","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nm.4336","article-title":"Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia","volume":"23","author":"Giustacchini","year":"2017","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3324\/haematol.2010.035006","article-title":"CD34(+)\/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab\/ozogamicin","volume":"97","author":"Herrmann","year":"2012","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3324\/haematol.2017.169946","article-title":"CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting","volume":"103","author":"Landberg","year":"2017","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","article-title":"Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche","volume":"19","author":"Ye","year":"2016","journal-title":"Cell Stem Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","article-title":"Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia","volume":"123","author":"Herrmann","year":"2014","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1182\/blood-2016-07-728873","article-title":"Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML","volume":"129","author":"Warfvinge","year":"2017","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/s41375-019-0684-5","article-title":"CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy","volume":"34","author":"Kinstrie","year":"2020","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1182\/blood-2015-11-679928","article-title":"Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor\u2013treated CML stem cells","volume":"128","author":"Zhang","year":"2016","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.exphem.2017.04.003","article-title":"Expression of CD25 on leukemic stem cells in BCR-ABL1 + CML: Potential diagnostic value and functional implications","volume":"51","author":"Sadovnik","year":"2017","journal-title":"Exp. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1182\/blood-2012-12-475194","article-title":"Monoclonal antibody targeting of IL-3 receptor \u03b1 with CSL362 effectively depletes CML progenitor and stem cells","volume":"123","author":"Nievergall","year":"2014","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/leu.2008.262","article-title":"beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia","volume":"23","author":"Hu","year":"2009","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Neviani","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_34","first-page":"341","article-title":"Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells","volume":"534","author":"Abraham","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood.2018875922","article-title":"A KLF4-DYRK2\u2013mediated pathway regulating self-renewal in CML stem cells","volume":"134","author":"Park","year":"2019","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/nm.4399","article-title":"Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells","volume":"23","author":"Kuntz","year":"2017","journal-title":"Nat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor\u2013induced cell death in Philadelphia chromosome\u2013positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1080\/15548627.2016.1162359","article-title":"ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells","volume":"12","author":"Karvela","year":"2016","journal-title":"Autophagy"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J. Clin. Invest."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","article-title":"Chronic myeloid leukemia stem cells","volume":"33","author":"Houshmand","year":"2019","journal-title":"Leukemia"},{"key":"ref_42","first-page":"1785","article-title":"BCR first exon sequences specifically activate the BCR\/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias","volume":"11","author":"Muller","year":"1991","journal-title":"Mol. Cell. Biol."},{"key":"ref_43","first-page":"342","article-title":"Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia","volume":"328","author":"Gordon","year":"1987","journal-title":"Nat. Cell Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1172\/JCI115985","article-title":"Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV","volume":"90","author":"Verfaillie","year":"1992","journal-title":"J. Clin. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"37525","DOI":"10.1074\/jbc.274.53.37525","article-title":"The adapter protein Crkl links Cbl to C3G after integrin ligation and enhances cell migration","volume":"274","author":"Uemura","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_46","first-page":"1149","article-title":"Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing, p.2.1.0.B.C.R.\/.A.B.L","volume":"11","author":"Salgia","year":"1995","journal-title":"Oncogene"},{"key":"ref_47","first-page":"325","article-title":"The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity","volume":"124","author":"Jackson","year":"1994","journal-title":"J. Cell Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1172\/JCI119520","article-title":"BCR\/ABL induces multiple abnormalities of cytoskeletal function","volume":"100","author":"Salgia","year":"1997","journal-title":"J. Clin. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2003-01-0062","article-title":"Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development","volume":"102","author":"Wertheim","year":"2003","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/leu.2008.71","article-title":"Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis","volume":"22","author":"Thomas","year":"2008","journal-title":"Leukemia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/nm1489","article-title":"Requirement for CD44 in homing and engraftment of BCR-ABL\u2013expressing leukemic stem cells","volume":"12","author":"Krause","year":"2006","journal-title":"Nat. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3324\/haematol.2018.212365","article-title":"The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL\/TAL1 - CD44 axis","volume":"105","author":"Godavarthy","year":"2019","journal-title":"Haematologica"},{"key":"ref_53","unstructured":"Deininger, M.W., Vieira, S., Mendiola, R., Schultheis, B., Goldman, J.M., and Melo, J.V. (2000). BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res., 60."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1172\/JCI118820","article-title":"Bcr\/Abl expression stimulates integrin function in hematopoietic cell lines","volume":"98","author":"Bazzoni","year":"1996","journal-title":"J. Clin. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood-2013-11-538694","article-title":"Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche","volume":"123","author":"Krause","year":"2014","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/leu.2008.26","article-title":"Contributions of the Raf\/MEK\/ERK, PI3K\/PTEN\/Akt\/mTOR and Jak\/STAT pathways to leukemia","volume":"22","author":"Steelman","year":"2008","journal-title":"Leukemia"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Ilaria, R.L., and Van Etten, A.R. (1996). P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem., 271.","DOI":"10.1074\/jbc.271.49.31704"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ccr.2004.12.010","article-title":"Stat5 tetramer formation is associated with leukemogenesis","volume":"7","author":"Moriggl","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1182\/blood-2005-10-4110","article-title":"STAT5 signaling is required for the efficient induction and maintenance of CML in mice","volume":"107","author":"Ye","year":"2006","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-2141.2008.07221.x","article-title":"BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia","volume":"142","author":"Cordeu","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of bcr\/abl -positive leukaemia","volume":"2","author":"Hoelbl","year":"2010","journal-title":"EMBO Mol. Med."},{"key":"ref_62","first-page":"2269","article-title":"Bcr\/Abl activates transcription of the Bcl-X gene through STAT","volume":"96","author":"Gesbert","year":"2000","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V86.2.726.bloodjournal862726","article-title":"Phosphatidylinositol-3 kinase activity is regulated by BCR\/ABL and is required for the growth of Philadelphia chromosome-positive cells","volume":"86","author":"Skorski","year":"1995","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0092-8674(00)81883-8","article-title":"PI3K: Downstream AKTion Blocks Apoptosis","volume":"88","author":"Franke","year":"1997","journal-title":"Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1084\/jem.181.1.307","article-title":"Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene","volume":"181","author":"Sawyers","year":"1995","journal-title":"J. Exp. Med."},{"key":"ref_66","first-page":"1933","article-title":"Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines","volume":"96","author":"Jonuleit","year":"2000","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1182\/blood-2013-04-497040","article-title":"BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein","volume":"124","author":"Agarwal","year":"2014","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood-2015-11-681171","article-title":"Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases","volume":"127","author":"Dasgupta","year":"2016","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11899-007-0010-6","article-title":"Genomic instability: The cause and effect of BCR\/ABL tyrosine kinase","volume":"2","author":"Skorski","year":"2007","journal-title":"Curr. Hematol. Malign. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood-2003-02-0371","article-title":"Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate","volume":"103","author":"Mauro","year":"2004","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","article-title":"Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center","volume":"103","author":"Lahaye","year":"2005","journal-title":"Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000046636","article-title":"Cytogenetic and Molecular Genetic Evolution of Chronic Myeloid Leukemia","volume":"107","author":"Johansson","year":"2002","journal-title":"Acta Haematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/cncr.25015","article-title":"Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy","volume":"116","author":"Verma","year":"2010","journal-title":"Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/asheducation-2005.1.188","article-title":"Pathobiology of Lymphoid and Myeloid Blast Crisis and Management Issues","volume":"2005","author":"Ilaria","year":"2005","journal-title":"Hematology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.V95.4.1144.004k04_1144_1150","article-title":"Acquired loss of p53 induces blastic transformation in p210bcr\/abl-expressing hematopoietic cells: A transgenic study for blast crisis of human CML","volume":"95","author":"Honda","year":"2000","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/leu.2011.7","article-title":"p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells","volume":"25","author":"Peterson","year":"2011","journal-title":"Leukemia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.2020004834","article-title":"An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia","volume":"135","author":"Ko","year":"2020","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/leu.2014.272","article-title":"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status","volume":"28","author":"Schmidt","year":"2014","journal-title":"Leukemia"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1182\/blood-2007-05-091769","article-title":"BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia","volume":"111","author":"Ban","year":"2008","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Singh, M.M., Howard, A., Irwin, M.E., Gao, Y., Lu, X., Multani, A., and Chandra, J. (2012). Expression and Activity of Fyn Mediate Proliferation and Blastic Features of Chronic Myelogenous Leukemia. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0051611"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0145-2126(97)00006-4","article-title":"bcl-2 and c-myc Expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase","volume":"21","author":"Handa","year":"1997","journal-title":"Leuk. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/onc.2008.466","article-title":"MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family","volume":"28","author":"Beverly","year":"2009","journal-title":"Oncogene"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1038\/onc.2012.246","article-title":"MYC antagonizes the differ-entiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.)","volume":"32","author":"Ferrandiz","year":"2013","journal-title":"Oncogene"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.3324\/haematol.2018.193086","article-title":"BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia","volume":"103","author":"Srutova","year":"2018","journal-title":"Haematologica"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1158\/1541-7786.MCR-10-0356","article-title":"MYC in Chronic Myeloid Leukemia: Induction of Aberrant DNA Synthesis and Association with Poor Response to Imatinib","volume":"9","author":"Albajar","year":"2011","journal-title":"Mol. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/02841868309134332","article-title":"Splenic Irradiation in Chronic Myeloid Leukemia","volume":"22","author":"Hukku","year":"1983","journal-title":"Acta Radiol. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1445-5994.1981.tb03534.x","article-title":"Effect of High Dose Busulphan on Leukaemic Progenitor Cells in Chronic Myeloid Leukaemia","volume":"11","author":"Morstyn","year":"1981","journal-title":"Aust. N. Z. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/1097-0142(197204)29:4<1052::AID-CNCR2820290454>3.0.CO;2-7","article-title":"Hydroxyurea therapy in chronic myelogenous leukemia","volume":"29","author":"Kennedy","year":"1972","journal-title":"Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2141.1986.tb07576.x","article-title":"Chronic myelogenous leukaemia: Haematological remissions with alpha interferon","volume":"64","author":"Talpaz","year":"1986","journal-title":"Br. J. Haematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood.V69.3.961.961","article-title":"Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia","volume":"69","author":"Yoffe","year":"1987","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-\u03b1: A study of complete cytogenetic responders","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood"},{"key":"ref_95","first-page":"1033","article-title":"Complete cytogenetic and molecular responses to interferon-\u03b1-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer Interdiscip. Int. J. Am. Cancer Soc."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM197902153000702","article-title":"Disappearance of pH1-Positive Cells in Four Patients with Chronic Granulocytic Leukemia after Chemotherapy, Irradiation and Marrow Transplantation from an Identical Twin","volume":"300","author":"Fefer","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0140-6736(82)92736-2","article-title":"Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia","volume":"320","author":"Goldman","year":"1982","journal-title":"Lancet"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0140-6736(82)92737-4","article-title":"Successful allogeneic bone-marrow transplan-tation for patients in the accelerated phase of chronic granulocytic leukaemia","volume":"2","author":"McGlave","year":"1982","journal-title":"Lancet"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/(SICI)1096-8652(199701)54:1<61::AID-AJH9>3.0.CO;2-2","article-title":"Chronic myeloid leukemia as an immunological target","volume":"54","author":"Lim","year":"1997","journal-title":"Am. J. Hematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/leu.2008.148","article-title":"Immunotherapy for myeloid leukemias: Current status and future directions","volume":"22","author":"Smith","year":"2008","journal-title":"Leukemia"},{"key":"ref_102","unstructured":"Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., M\u00fcller, M., Druker, B.J., and Lydon, N.B. (1996). Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 56."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr\u2013Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","article-title":"The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL\u2013Positive Cells","volume":"90","author":"Deininger","year":"1997","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and Resistance to BCR-ABL1-Targeted Therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"ref_109","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes re-gression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance","volume":"16","author":"Shakespeare","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_111","first-page":"733","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/leu.2013.51","article-title":"Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib","volume":"27","author":"Efficace","year":"2013","journal-title":"Leukemia"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41568-020-0245-2","article-title":"Bone marrow niches in haematological malignancies","volume":"20","author":"Bonnet","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fonc.2018.00194","article-title":"Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission","volume":"8","author":"Bocchia","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/nrm3598","article-title":"The mechanisms of Hedgehog signalling and its roles in development and disease","volume":"14","author":"Briscoe","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.stem.2009.03.015","article-title":"Hedgehog Signaling Is Dispensable for Adult Hematopoietic Stem Cell Function","volume":"4","author":"Gao","year":"2009","journal-title":"Cell Stem Cell"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"25476","DOI":"10.1038\/srep25476","article-title":"Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia","volume":"6","author":"Irvine","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4161\/15548627.2014.994368","article-title":"Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia","volume":"11","author":"Zeng","year":"2015","journal-title":"Autophagy"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K\u2013AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1038\/cddis.2013.309","article-title":"PI3K\/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor","volume":"4","author":"Airiau","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"9666","DOI":"10.1038\/s41598-019-46132-9","article-title":"MicroRNA signature refine response prediction in, C.M.L","volume":"9","author":"Alves","year":"2019","journal-title":"Sci Rep."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.leukres.2015.07.008","article-title":"Silencing of miR-21 sensitizes CML CD34+ stem\/progenitor cells to imatinib-induced apoptosis by blocking PI3K\/AKT pathway","volume":"39","author":"Wang","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Trojani, A., Pungolino, E., Molin, A.D., Lodola, M., Rossi, G., D\u2019Adda, M., Perego, A., Elena, C., Turrini, M., and Borin, L. (2019). Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+\/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0218444"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo","volume":"124","author":"Gallipoli","year":"2014","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jnci\/djt006","article-title":"Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1\u2013BCR-ABL\u2013JAK2 Complex","volume":"105","author":"Chen","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41375-019-0427-7","article-title":"Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling","volume":"33","author":"Kuepper","year":"2019","journal-title":"Leukemia"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1038\/leu.2017.87","article-title":"Combined inhibition of beta-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo","volume":"31","author":"Zhou","year":"2017","journal-title":"Leukemia"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.3324\/haematol.2019.219261","article-title":"Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem\/progenitor cells in a murine model","volume":"105","author":"Carter","year":"2020","journal-title":"Haematologica"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"355ra117","DOI":"10.1126\/scitranslmed.aag1180","article-title":"Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells","volume":"8","author":"Carter","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/10428190400012029","article-title":"Interferon a and T-cell responses in chronic myeloid leukemia","volume":"46","author":"Burchert","year":"2005","journal-title":"Leuk. Lymphoma"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3324\/haematol.2009.021246","article-title":"The response to imatinib and interfer-on-alpha is more rapid than the response to imatinib alone: A retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase","volume":"95","author":"Palandri","year":"2010","journal-title":"Haematologica"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia","volume":"28","author":"Burchert","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nrm3841","article-title":"The growing landscape of lysine acetylation links metabolism and cell signalling","volume":"15","author":"Choudhary","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.lfs.2018.09.040","article-title":"Synergistic activity of imatinib and AR-42 against chronic myeloid leukemia cells mainly through HDAC1 inhibition","volume":"211","author":"Wei","year":"2018","journal-title":"Life Sci."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/cas.12965","article-title":"Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells","volume":"107","author":"Matsuda","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1515\/med-2017-0014","article-title":"Impact of chromosomal rearrangement upon DNA methylation patterns in leukemia","volume":"12","author":"Byun","year":"2017","journal-title":"Open Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.ejca.2009.04.005","article-title":"Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia","volume":"45","author":"Agirre","year":"2009","journal-title":"Eur. J. Cancer."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition","volume":"6","author":"Scott","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1016\/j.ejca.2013.07.147","article-title":"Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis","volume":"49","author":"Ghez","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1080\/10428194.2017.1397666","article-title":"Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia","volume":"59","author":"Ruggiu","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3892\/ijo.2014.2313","article-title":"Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia","volume":"44","author":"Shao","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1182\/blood-2013-07-516807","article-title":"The core autophagy protein ATG4B is a potential bi-omarker and therapeutic target in CML stem\/progenitor cells","volume":"123","author":"Rothe","year":"2014","journal-title":"Blood"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41375-018-0252-4","article-title":"Targeting quiescent leukemic stem cells using second generation autophagy inhibitors","volume":"33","author":"Baquero","year":"2019","journal-title":"Leukemia"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/s41375-019-0700-9","article-title":"A randomised phase II trial of hy-droxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease","volume":"34","author":"Horne","year":"2020","journal-title":"Leukemia"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"35293","DOI":"10.18632\/oncotarget.9182","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy dis-continuation","volume":"7","author":"Chomel","year":"2016","journal-title":"Oncotarget"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.clml.2017.11.006","article-title":"Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia","volume":"18","author":"Goldberg","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/cncr.31977","article-title":"The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors","volume":"125","author":"Farina","year":"2019","journal-title":"Cancer"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/leu.2015.45","article-title":"Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia","volume":"29","author":"Burchert","year":"2015","journal-title":"Leukemia"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2141.2011.08939.x","article-title":"Increased natural killer cells and decreased CD3+CD8+CD62L+ T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib","volume":"157","author":"Ohyashiki","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/leu.2017.9","article-title":"Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML","volume":"31","author":"Inselmann","year":"2017","journal-title":"Leukemia"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/cas.13430","article-title":"Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation","volume":"109","author":"Kumagai","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Irani, Y.D., Hughes, A., Clarson, J., Kok, C.H., Shanmuganathan, N., White, D.L., Yeung, D.T., Ross, D.M., Hughes, T.P., and Yong, A.S. (2020). Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. Br. J. Haematol.","DOI":"10.1111\/bjh.16718"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3324\/haematol.2018.194894","article-title":"Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan","volume":"103","author":"Takahashi","year":"2018","journal-title":"Haematologica"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature22314","article-title":"Cancer progression by reprogrammed BCAA me-tabolism in myeloid leukaemia","volume":"545","author":"Hattori","year":"2017","journal-title":"Nature"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1038\/ncomms9039","article-title":"Dipeptide species regulate p38MAPK\u2013Smad3 signalling to maintain chronic myelogenous leukaemia stem cells","volume":"6","author":"Naka","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1182\/blood-2011-06-361691","article-title":"Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis","volume":"119","author":"Yuan","year":"2012","journal-title":"Blood"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib","volume":"21","author":"Li","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1172\/JCI127080","article-title":"SIRT1 regulates metabolism and leukemogenic potential in CML stem cells","volume":"129","author":"Abraham","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2014.07.048","article-title":"Cell-State-Specific Metabolic Dependency in Hematopoiesis and Leukemogenesis","volume":"158","author":"Wang","year":"2014","journal-title":"Cell"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2018-99-113960","article-title":"PKM2 Mediates Chronic Myeloid Leukemia Imatinib Resistance By Regulating Glycolysis Energy Metabolism","volume":"132","author":"Tong","year":"2018","journal-title":"Blood"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"jcs201707","DOI":"10.1242\/jcs.201707","article-title":"The bone marrow microenvironment in health and disease at a glance","volume":"131","author":"Kumar","year":"2018","journal-title":"J. Cell Sci."},{"key":"ref_172","first-page":"269","article-title":"Direct measurement of local oxygen concentration in the bone marrow of live animals","volume":"508","author":"Spencer","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1182\/blood-2011-10-387381","article-title":"HIF1\u03b1 is required for survival maintenance of chronic myeloid leukemia stem cells","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Bhatia, R., Munthe, H.A., and Verfaillie, C.M. (1999). Role of abnormal integrin-cytoskeletal interactions in impaired beta1 integrin function in chronic myelogenous leukemia hematopoietic progenitors. Exp. Hematol., 27.","DOI":"10.1016\/S0301-472X(99)00084-3"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1172\/JCI117333","article-title":"Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function","volume":"94","author":"Bhatia","year":"1994","journal-title":"J. Clin. Investig."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2141.2006.06435.x","article-title":"Beta1 integrin mediated adhesion increases Bim protein degradation and con-tributes to drug resistance in leukaemia cells","volume":"136","author":"Hazlehurst","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41375-020-0866-1","article-title":"Specific, targetable interactions with the mi-croenvironment influence imatinib-resistant chronic myeloid leukemia","volume":"34","author":"Kumar","year":"2020","journal-title":"Leukemia"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.stem.2020.04.005","article-title":"Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors","volume":"27","author":"Rothe","year":"2020","journal-title":"Cell Stem Cell"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.leu.2400653","article-title":"Activation of beta1 integrins on CML progenitors reveals cooper-ation between beta1 integrins and CD44 in the regulation of adhesion and proliferation","volume":"11","author":"Lundell","year":"1997","journal-title":"Leukemia"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1535-7163.MCT-07-0042","article-title":"CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells","volume":"7","author":"Jin","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1158\/1535-7163.MCT-13-0410","article-title":"Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo","volume":"13","author":"Beider","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/leu.2011.360","article-title":"Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib","volume":"26","author":"Weisberg","year":"2011","journal-title":"Leukemia"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1182\/blood-2011-05-355396","article-title":"Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML","volume":"120","author":"Agarwal","year":"2012","journal-title":"Blood"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","article-title":"Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia","volume":"21","author":"Zhang","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.stem.2019.02.018","article-title":"Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells","volume":"24","author":"Agarwal","year":"2019","journal-title":"Cell Stem Cell."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ccr.2011.10.012","article-title":"IL-6 Controls Leukemic Multipotent Progenitor Cell Fate and Contributes to Chronic Myelogenous Leukemia Development","volume":"20","author":"Reynaud","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ccell.2015.04.004","article-title":"Treatment of Chronic Myelogenous Leukemia by Blocking Cytokine Alterations Found in Normal Stem and Progenitor Cells","volume":"27","author":"Welner","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1182\/blood.V78.6.1476.1476","article-title":"Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: A novel application for inhibitors of IL-1 activity","volume":"78","author":"Estrov","year":"1991","journal-title":"Blood"},{"key":"ref_189","first-page":"214","article-title":"Suppression of chronic myelogenous leukemia colony growth by interleukin-4","volume":"7","author":"Estrov","year":"1993","journal-title":"Leukemia"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"12167","DOI":"10.1074\/jbc.RA119.008037","article-title":"Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7\/JAK1\/STAT5 pathway","volume":"294","author":"Zhang","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/sj.leu.2402678","article-title":"Interleukin-3 protects Bcr-Abl-transformed hem-atopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors","volume":"16","author":"Dorsey","year":"2002","journal-title":"Leukemia"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukae-mia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/nm.3364","article-title":"Differential regulation of myeloid leukemias by the bone marrow microenvironment","volume":"19","author":"Krause","year":"2013","journal-title":"Nat. Med."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ccr.2011.05.007","article-title":"Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia","volume":"19","author":"Schmidt","year":"2011","journal-title":"Cancer Cell."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1172\/JCI81135","article-title":"The biology and function of exosomes in cancer","volume":"126","author":"Kalluri","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/ijc.26217","article-title":"Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis","volume":"130","author":"Taverna","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.canlet.2014.03.009","article-title":"Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an Interleukin 8-dependent survival of leukemia cells","volume":"348","author":"Corrado","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.7150\/thno.34813","article-title":"Chronic myelogenous leukemia cells remodel the bone marrow niche via exosome-mediated transfer of miR-320","volume":"9","author":"Gao","year":"2019","journal-title":"Theranostics"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/1\/117\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:09:19Z","timestamp":1760159359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/1\/117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,10]]},"references-count":198,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["cells10010117"],"URL":"https:\/\/doi.org\/10.3390\/cells10010117","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,10]]}}}